GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today reported its financial and operational results for the second quarter of 2026.
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- On June 4, 2026, Barrack Rodos & Bacine filed a class action lawsuit seeking to represent purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”). Captioned Basma v.
PHILADELPHIA, June 10, 2026 (GLOBE NEWSWIRE) -- On June 4, 2026, Barrack Rodos & Bacine filed a class action lawsuit seeking to represent purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”). Captioned Basma v. GeneDx Holdings Corp., No. 26-cv-00880 (D. Conn.), the lawsuit charges GeneDx and certain of its top exe...
NEW YORK, June 6, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
SAN FRANCISCO, June 4, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33.42 (-49%) on May 5, 2025 after the company announced a massive Q1 2026 earnings miss, a tenfold increase in net loss, and a drastic reduction in full-year 2026 guidance. The stock's move lower wiped out over $900 million from GeneDx's market capitalization in a sin...
SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33.42 (-49%) on May 5, 2025 after the company announced a massive Q1 2026 earnings miss, a tenfold increase in net loss, and a drastic reduction in full-year 2026 guidance. The stock's move lower wiped out over $900 million from GeneDx's market capitalization in a sin...